# Neoadjuvant GW572016 to Treat Breast Cancer

> **NCT00206427** · PHASE2 · COMPLETED · sponsor: **Baylor Breast Care Center** · enrollment: 49 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** GW572016
- **DRUG:** lapatinib

## Key facts

- **NCT ID:** NCT00206427
- **Lead sponsor:** Baylor Breast Care Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2011-06
- **Final completion:** 2012-02
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2021-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00206427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00206427, "Neoadjuvant GW572016 to Treat Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00206427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*